JOURNAL OF
Veterinary Science

Original Article

Evaluation of a side population of canine lymphoma cells using Hoechst 33342 dye

Myung-Chul Kim[1], Susan D'Costa[2], Steven Suter[3], Yongbaek Kim[1,*]

[1]The Laboratory of Clinical Pathology and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul 151-742, Korea
Departments of [2]Population Health and Pathobiology, and [3]Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607, USA

  Cancer stem cell (CSC) research has increased exponentially to gain further insight into the mechanisms underlying both carcinogenesis and chemotherapy resistance. The present study was performed to explore the potential value of a side population (SP) assay for identifying and characterizing putative CSCs among canine lymphoma cells. Canine lymphoma cells from cell lines and clinical samples were subjected to the SP assay consisting of Hoechst 33342 staining and subsequent flow cytometric analysis. The SP assay revealed various amounts of a SP fraction among the canine lymphoma cells. The percentages of SP were not affected by inhibitors of membrane transporters, verapamil hydrochloride, or fumitremorgin C. Most of the canine lymphoma cells expressed high levels of Bmi-1 and membrane transporter proteins such as ABCG2 and phosphorylated (p)-glycoprotein. This investigation lays the groundwork for further studies of the biological behaviors and molecular characteristics of CSCs in cases of canine lymphoma.

Keywords: dog, flow cytometry, Hoechst 33342, lymphoma, side population

Introduction

  Recently published literature has provided molecular evidence indicating that the dog as a highly suitable biomedical model for cancer research [22]. Canine lymphoma is biologically and phenotypically similar to a high-grade variant of non-Hodgkin's lymphoma (NHL) in humans called diffuse large B-cell lymphoma (DLBCL) [2]. Canine lymphoma is the most common hematopoietic

tumor (83%) in dogs. The annual incidence of canine lymphoma is ~84/100,000 dogs among animals 10 to 11 years old and accounts for up to ~24% of all cases of malignant neoplasia [11]. Multicentric lymphoma affecting the peripheral lymph nodes is the most common form in dogs although the disease can arise at virtually any location. Similar to human NHL, canine lymphoma can result from the malignant transformation of either B or T cells. Approximately 75~80% of lymphomas are B cell in origin [11]. In humans, the incidence of B-cell lymphoid neoplasm is about 26/100,000 per year with approximately 67,000 cases/year diagnosed in the United States [14].

  Canine lymphoma is treated with the same drugs as human NHL using L-CHOP protocol, which has been considered as the most commonly administered reagents including vincristine, cyclophosphamide, L-asparaginase, doxorubicin, and prednisone. In general, complete remission is achieved in ~80% of treated dogs with median survival times of 290 days; only 10% of dogs survive 2 years or longer [12]. The vast majority of canines succumb to recrudescent disease that is resistant to all known chemotherapy drugs.

  The considerable range of survival times is due to the fact that lymphoma subtypes have different prognoses [16] and may require different treatments. For example, animals with canine T-cell lymphoma exhibit shorter survival times than ones with B-cell lymphoma [7]. Further knowledge beyond whether a lymphoma is of B or T cell origin is urgently needed to optimize specific treatment plans, understand the molecular underpinnings of chemotherapy resistance, and develop more targeted, less toxic treatment strategies.

  Recent stem cell biology studies have suggested that

*Corresponding author: Tel: +82-2-880-1273; Fax: +82-2-873-1213; E-mail: yongbaek@snu.ac.kr

some cancers contain stem-like cells (cancer stem cells or CSCs) that exist as a small subpopulation within tumor tissues [18]. A side population (SP) assay consisting of Hoechst 33342 staining and subsequent flow cytometic analysis has recently been used to identify both malignant and normal stem cells [15]. This SP assay is based on the observation that stem cells express high levels of specific ATP-binding cassette (ABC) transporters that actively remove drugs from cells and protect against cytotoxic agents. Hoechst 33342 dye accumulates within the cytoplasm of most differentiated cells. However, this does not occur in stem cells because the dye is actively removed by an ABC transporter called breast cancer resistance protein (BCRP) [15]. Cells that contain a low level of Hoechst 33342 fluorescence are referred to as an SP that can be separated by flow cytometry-assisted cell sorting (FACS). SP fractions from normal and malignant tissues are enriched with stem cells [15].

The current study was performed to explore the potential value of the SP assay for identifying and characterizing putative CSCs in canine lymphoid malignancies. Results from this investigation indicated that the SP assay could identify a subpopulation in canine lymphoma cells. This subpopulation was not abrogated by treatment with chemical inhibitors of ABC transporters. Further studies on methodologies for CSC identification and characterization are warranted.

Materials and Methods

Canine neoplastic lymphoid cells

Two well-characterized canine lymphoid B-cell lines (GL-1 and 17-71 cells) and a canine T-cell lymphoma cell line (CL-1) provided by Dr. Steven Suter (North Carolina State University, USA) were used in this study. The cell lines were maintained at 37°C in a humidified atmosphere in RPMI (Roswell Park Memorial Institute) medium supplemented with 10% FBS (Fetal Bovine Serum), 10 mM HEPES, 1 mM sodium pyruvate, and 100 U/100 mg/mL penicillin/streptomycin (Sigma Aldrich, USA). GL-1 cells represent an immature B-cell leukemia while 17-71 cells represent a B-cell malignancy.

Neoplastic lymphoid cells were obtained from the lymph nodes of dogs diagnosed with lymphoma at North Carolina State University and Seoul National University (Korea). The diagnosis of canine B-cell lymphoma was made based on the clinical signs, cytology of fine needle aspirates from the enlarged peripheral lymph nodes, and flow cytometry (for immunophenotyping). For this study, neoplastic B-lymphoblasts were isolated via fine needle aspiration from the enlarged peripheral lymph nodes of five dogs during initial staging (before chemotherapy was initiated). The neoplastic cells were cultured overnight in RPMI supplemented with 10% FBS, 10 mM HEPES, 1 mM sodium pyruvate, and 100 U/100 mg/mL penicillin/streptomycin (Sigma Aldrich), and then stained with Hoechst 33342 dye.

SP assay

All of the lymphoid cells were grown in RPMI medium supplemented with 100 U/100 mg/mL penicillin/streptomycin (Sigma Aldrich) and 10% FBS. The Hoechst 33342 staining procedure was based on the method described by Goodell *et al.* [1] with slight modification. Briefly, the cells (10^6 cells/mL) were re-suspended in the pre-warmed media containing 2% FBS and then incubated for 90 min at 37°C with Hoechst 33342 stain (5 μg/mL final concentration; Sigma, USA) with intermittent mixing. After incubation, the cells were centrifuged at 480 × g for 5 min and washed in a cold 2% FBS/PBS solution. Hoechst 33342 staining was observed using a FACSan flow cytometer (Becton-Dickinson, USA) at 357 nm to detect Hoechst Blue with a 424/44 broad pass (BP) filter and Hoechst Red with a 675/20 BP filter. At least 50,000 events within the live gate were examined to define an SP region.

Validation of the SP fraction

SP regions were generally confirmed by treatment with chemical inhibitors of an ABC transporter, ABCG2 (ATP-binding cassette, sub-family G, member 2, also known as BCRP). Before the flow cytometric analysis, the cells were treated with 25, 50, or 100 μM verapamil hydrochloride (Sigma, USA) or 10 μM fumitremorgin C (EMD Biosciences, USA) at 37°C for 0 ~ 20 min prior to Hoechst 33342 staining in order to monitor the prevention of Hoechst 33342 dye efflux.

Western blot assay

Cellular lysates were prepared by re-suspending the canine neoplastic lymphoid cells in Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, USA) containing protease (Roche Diagnostic, USA) and phosphatase inhibitors (Thermo Fisher Scientific) at 4°C. The lysates were then sonicated for 5 min by using a Vibra-Cell sonicator (Fisher, Canada), centrifuged for 10 min at 23,000 × g at 4°C, and concentrated using a Micron cellulose filter (EMD Millipore, USA). Protein concentration was measured using a detergent-compatible protein assay reagent (Bio-Rad Laboratories, USA). Gel electrophoresis as well as membrane transfer, blocking, and incubation with antibody were performed as previously described by Kai *et al.* [5]. Primary antibodies used for this study were specific for ABCG2 [1 : 500 dilution, rat monoclonal antibody (BXP-53) against BCRP/ABCG2; Abcam, USA], phosphorylated (p)-glycoprotein [1 : 75 dilution, mouse monoclonal antibody (C219); EMD, USA], Nanog (1 : 600 dilution, rabbit polyclonal antibody; Abcam), and Bmi (1 : 1,000 dilution, mouse monoclonal antibody; Abcam).

Chemiluminescence was generated using Enhanced Chemiluminescent (ECL) Western Blotting Substrate (Thermo Fisher Scientific). The blots were stripped with Restore Western blot stripping buffer (Thermo Fisher Scientific) and re-probed with antibody against GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) as an internal loading control.

Results

### SP assay for detecting neoplastic lymphoid cells

Canine lymphoma cells recovered from three cell lines and the lymph nodes of five clinical cases of canine lymphoma were subjected to an SP assay. The clinical cases were diagnosed as canine B-cell lymphoma based on clinical signs, cytology of fine needle aspirates from the enlarged peripheral lymph nodes, and flow cytometry for immunophenotyping. Following Hoechst 33342 staining, the subsequent flow cytometric analysis revealed a clearly delineated subpopulation of cells (Fig. 1). Staining intensities and patterns of the subpopulation cells observed with flow cytometric analysis were consistent with those of SP cells previously described in published study [5]. The subpopulation accounted for 0.13% of GL-1 cells, 4.07% of 17-71 cells, and 0.73% of CL-1 cells. Cells prepared from the clinical cases of canine lymphoma contained much higher percentages of the subpopulation cells ranging from 68 to 78%.

The SP fraction should be reduced or abrogated by treatment with verapamil hydrochloride, an inhibitor of ABCG2 [5]. Unexpectedly, treatment with verapamil hydrochloride did not affect the subpopulation cell percentage for the canine lymphoma cells we examined (Fig. 1). Moreover, fumitremorgin C, another specific inhibitor of ABCG2 [17], did not affect the abundance of subpopulation cells among the canine lymphoma cells.


Fig. 1. Flow cytometric analysis of canine lymphoma cells. Hoechst 33342 staining profiles were acquired by detecting Hoechst Blue with a 424/44 broad pass (BP) filter and Hoechst Red with a 675/20 BP filter. The left column (Hoechst) represents Hoechst 33342 staining and flow cytometric analysis. The middle column represents the effects of verapamil hydrochloride on Hoechst 333342 staining. The right column represents the effects of fumitremorgin C (FTC) on Hoechst 33342 staining. The efflux of Hoechst 33342 dye was not significantly inhibited by treatment with verapamil hydrochloride (middle column) or fumitremorgin C (right column). GL-1: a canine B lymphoma cell line, CL-1: a canine T lymphoma cell line, 17-71: a canine B cell lymphoid leukemia cell line, Lymphoma: lymphoma cells obtained from a clinical case of canine B cell lymphoma.

Fig. 2. Western blot assay for ABCG2 and p-glycoprotein expression in canine lymphoma cell lines. High levels of ABCG2 protein were detected in 17-71 and CL-1 cells but not in GL-1 cells. In contrast, p-glycoprotein was highly expressed in GL-1 cells while 17-71 and CL-1 cells had a lower level of p-glycoprotein. ABCG2: ATP-binding cassette, sub-family G, member 2.

Fig. 3. Western blot assay for Bmi-1 and p-glycoprotein expression in canine lymphoma cells. High levels of Bmi-1 protein were detected in GL-1 and CL-1 cells as well as one of the five clinical lymphoma cases. Cells from the four other clinical cases of canine lymphomas expressed lower levels of Bmi-1. P-glycoprotein was highly expressed in one clinical lymphoma case, but the four other cases expressed lower levels of this protein. GAPDH was included as a loading control. GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.

Fig. 4. Western blot assay for Nanog and ABCG2 expression in canine lymphoma cells. All of the lymphoma cells examined had either low or non-existent levels of Nanog expression. NCCIT cells, an embryonic carcinoma cell line, were included as a positive control for Nanog expression. Higher levels of ABCG2 protein were detected in the clinical cases of canine lymphomas compared to the canine lymphoma cell lines. GAPDH was included as a loading control.

Expression levels of ABC transporters and stemness genes

The canine lymphoma cells were subjected to Western blotting to measure the expression levels of ABC transporters and stemness-related genes. High expression levels of ABCG2 were detected in 17-71 and CL-1 cells while only a low level was observed in GL-1 cells (Fig. 2). The levels of p-glycoprotein were significantly higher in the GL-1 than the 17-71 or CL-1 cells (Fig. 2). ABCG2 were highly expressed in the clinical canine lymphoma cell samples, but the expression levels of p-glycoproteins were lower in most of these samples. Bmi-1 was highly expressed in the canine lymphoma cells while most clinical samples exhibited lower levels of this factor (Fig. 3). Nanog expression was rarely detected in the canine lymphoma cells we examined while NCCIT (Human embryonic carcinoma cell line) cells expressed a high level of Nanog (Fig. 4).

Discussion

CSC research is still in its infancy largely due to inherent drawbacks of current CSC identification methods. Flow cytometry using cell surface markers have been successfully applied to mice and human samples to characterize stem cell populations [9]. Different cell surface markers for isolating and targeting stem cells, including CD133, CD24, CD44, CD34, and integrins, have been described [9,10,18,21]. The work being done to identify biomarker surrogates for CSCs is rapidly progressing. Despite the extensive studies on various tissues and species, stem cell markers are scarce, the assays are difficult to standardize, and the actual hierarchy of the assays remains to be defined. In order to circumvent the limitations of existing assays using surrogate cell surface markers, extensive efforts have been made to develop alternative methods that could be universally applied to various tissue types. The most promising of these

alternative methods is the SP assay consisting of Hoechst 33342 staining and subsequent flow cytometry [13]. Recently, the ALDEFLUOR assay exploiting cellular aldehyde dehydrogenase 1 (ALDH1) activity was developed and has been evaluated as a tool for CSC identification [10]. The present study was performed to evaluate the potential value of the SP assay for identifying and characterizing putative CSCs in canine lymphoma cell populations.

The SP assay is based on the overexpression of an ABC transporter, ABCG2, in stem cells [1]. This molecule removes fluorescent dyes such as Hoechst 33342 or Rhodamin 123 from stem cells, a property not found in differentiated cells. Cells with the capacity to remove dyes have been referred to SP cells as they fall to the "side" of the bulk of positively labeled cells in flow cytometric plots [1]. Previous studies have demonstrated that the SP fractions from normal and cancer tissues are enriched with cells possessing stem cell properties [3,15,20]. On the other hand, more recent investigations have suggested that the SP assay can enrich CSCs only partially and not exclusively [5,21]. The present study showed that the SP assay identified a wide range of SP fractions among canine lymphoma cells. An alternative SP assay using another dye, Rhodamin 123, could also help identify the SP of canine lymphoma cells.

It was not unexpected that the SP fraction of canine lymphoma cells was not altered by treatment with verapamil hydrochloride or fumitremorgin C. Membrane-spanning ABC transporters, ABCG2 and P-gp, are highly expressed in normal and cancerous stem cells [6]. SP contents in cancer cell populations should be significantly reduced by treatment with verapamil hydrochloride, a specific inhibitor of ABCG2, suggesting that the expression of ABCG2 is a major molecular determinant of the SP cell phenotypes [20]. However, the SP fraction of the canine lymphoma cells was not reduced or abrogated by treatment with verapamil hydrochloride. In humans, verapamil hydrochloride is a specific inhibitor of ABCG2. Verapamil hydrochloride exerts inhibitory effects on p-glycoprotein function by competing with substrate drugs for binding p-glycoprotein. Fumitremorgin C is known as a potent and selective BCRP inhibitor [17]. Treatment with this compound did not affect the SP fraction of canine lymphoma cells. This may be due to species-specific differences in the inhibitory effects on ABC transporters [19]. Alternatively, the SP fraction of canine lymphoma cells may have unknown means to resist to the inhibitory effects of the compounds.

Dogs provide an excellent model of naturally occurring human DLBCL for a variety of reasons [2]. Canines provide additional advantages over traditional murine xenograft models in that they possess a spectrum of genetic diversity that is not present in most laboratory mouse

strains. This allows application of genomic strategies similar to those used in humans such as subclassification of tumors according to gene expression patterns [4]. Furthermore, naturally occurring DNA polymorphisms can help identify variants that influence lymphoma development or progression, thereby providing genetic clues for understanding disease biology [8]. An additional advantage is that canine lymphomas are an excellent model of chemoresistant disease. Despite treatment with chemotherapy regimens similar to those used for humans, dogs invariably die from their disease and so represent the segment of humans in most need of new treatment strategies. Finally, clinical data from dogs can be acquired within a much shorter time frame than from studies of human DLBCL because dogs naturally experience more rapid disease progression and relapse.

In summary, the SP assay evaluating canine lymphoma cells failed to detect an appropriate subpopulation of cells that were enriched with CSCs. Further studies of CSCs in canine lymphoma cell populations by other methodologies using cell surface markers or molecular markers should be attempted in order to help understand the disease pathogenesis. Characterization of putative canine lymphoid CSCs could provide further insight into the molecular underpinnings of both lymphoid carcinogenesis and chemotherapy resistance. This could lay the groundwork for the development of a novel CSC-specific therapeutic regimen.

Acknowledgments

References

1. **Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC.** Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, **183**, 1797-1806.

2. **Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Hurvitz AI, Lieberman PH.** Lymphomas in dogs: a morphologic, immunologic, and clinical study. Cancer 1990, **66**, 480-490.

3. **Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M.** Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, **24**, 506-513.

4. **Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, Chen IM, Atlas SR, Kang H, Ar K, Wilson CS, Wharton W, Murphy M, Devidas M, Carroll AJ, Borowitz MJ, Bowman WP, Downing JR, Relling M, Yang J, Bhojwani D, Carroll WL, Camitta B, Reaman GH, Smith M, Hunger SP, Willman CL.** Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, **116**, 4874-4884.

5. **Kai K, D'Costa S, Yoon BI, Brody AR, Sills RC, Kim Y.** Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer 2010, **70**, 146-151.

6. **Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K.** The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 2002, **8**, 22-28.

7. **Kiupel M, Teske E, Bostock D.** Prognostic factors for treated canine malignant lymphoma. Vet Pathol 1999, **36**, 292-300.

8. **Levine RL.** Inherited susceptibility to pediatric acute lymphoblastic leukemia. Nat Genet 2009, **41**, 957-958.

9. **Lobo NA, Shimono Y, Qian D, Clarke MF.** The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, **23**, 675-699.

10. **Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl-Atzwanger B, Walzer SM, Windhager R, Leithner A.** Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS One 2012, **7**, e43664.

11. **MacEwen EG.** Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990, **9**, 125-136.

12. **MacEwen EG, Hayes AA, Matus RE, Kurzman I.** Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981). J Am Vet Med Assoc 1987, **190**, 564-568.

13. **Montanaro F, Liadaki K, Schienda J, Flint A, Gussoni E, Kunkel LM.** Demystifying SP cell purification: viability, yield, and phenotype are defined by isolation parameters. Exp Cell Res 2004, **298**, 144-154.

14. **Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS.** Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, **107**, 265-276.

15. **Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG.** Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2$^+$ and ABCG2$^-$ cancer cells are similarly tumorigenic. Cancer Res 2005, **65**, 6207-6219.

16. **Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Fournel-Fleury C.** Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Vet J 2004, **167**, 158-166.

17. **Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM.** Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000, **60**, 47-50.

18. **Reya T, Morrison SJ, Clarke MF, Weissman IL.** Stem cells, cancer, and cancer stem cells. Nature 2001, **414**, 105-111.

19. **Suzuyama N, Katoh M, Takeuchi T, Yoshitomi S, Higuchi T, Asashi S, Yokoi T.** Species differences of

inhibitory effects on P-glycoprotein-mediated drug transport. J Pharm Sci 2007, **96**, 1609-1618.

20. **Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK.** Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A 2006, **103**, 11154-11159.

21. **Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G.** Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 2013, **27**, 13-24.

22. **Vail DM, MacEwen EG.** Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000, **18**, 781-792.